Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology, published by Elsevier, demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative complement pathway, halts cancer growth and alters the tumor microenvironment.